Insulet Co. (NASDAQ:PODD) Shares Purchased by Ayrshire Capital Management LLC

Ayrshire Capital Management LLC increased its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 34.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,988 shares of the medical instruments supplier's stock after buying an additional 5,911 shares during the quarter. Insulet comprises approximately 2.9% of Ayrshire Capital Management LLC's portfolio, making the stock its 16th largest position. Ayrshire Capital Management LLC's holdings in Insulet were worth $6,001,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Baillie Gifford & Co. boosted its holdings in Insulet by 20.7% during the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier's stock valued at $529,669,000 after acquiring an additional 389,639 shares during the period. Geode Capital Management LLC lifted its position in shares of Insulet by 1.3% during the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier's stock worth $403,339,000 after purchasing an additional 22,850 shares in the last quarter. Clearbridge Investments LLC boosted its stake in shares of Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier's stock valued at $270,364,000 after purchasing an additional 75,526 shares during the period. Westfield Capital Management Co. LP grew its holdings in shares of Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock valued at $175,697,000 after purchasing an additional 163,388 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier's stock worth $148,091,000 after buying an additional 193,839 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PODD. Morgan Stanley boosted their price objective on shares of Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a research report on Monday, November 11th. JPMorgan Chase & Co. raised their price objective on Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a report on Thursday, December 12th. Citigroup boosted their target price on Insulet from $283.00 to $310.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. Raymond James raised their price target on Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a research note on Monday, October 14th. Finally, Barclays boosted their price objective on Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $272.81.

Insider Activity

In related news, CAO Lauren Budden sold 915 shares of the business's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.47% of the company's stock.

Insulet Trading Down 0.4 %

Shares of NASDAQ PODD traded down $0.95 on Tuesday, reaching $267.04. 472,937 shares of the company traded hands, compared to its average volume of 485,355. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $18.73 billion, a PE ratio of 45.73, a P/E/G ratio of 4.12 and a beta of 1.22. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.77. The company has a 50 day moving average of $264.57 and a 200 day moving average of $230.93.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.